These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 9770335

  • 1. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis.
    Keul R, Heinrich PC, Müller-newen G, Muller K, Woo P.
    Cytokine; 1998 Sep; 10(9):729-34. PubMed ID: 9770335
    [Abstract] [Full Text] [Related]

  • 2. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.
    De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A.
    J Clin Invest; 1994 May; 93(5):2114-9. PubMed ID: 8182142
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
    Peake NJ, Khawaja K, Myers A, Nowell MA, Jones SA, Rowan AD, Cawston TE, Foster HE.
    Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
    [Abstract] [Full Text] [Related]

  • 4. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H, Wiersbowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [Abstract] [Full Text] [Related]

  • 5. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.
    Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P.
    J Clin Invest; 1998 Oct 01; 102(7):1369-76. PubMed ID: 9769329
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study.
    Bagli M, Papassotiropoulos A, Hampel H, Becker K, Jessen F, Bürger K, Ptok U, Rao ML, Möller HJ, Maier W, Heun R.
    Eur Arch Psychiatry Clin Neurosci; 2003 Feb 01; 253(1):44-8. PubMed ID: 12664314
    [Abstract] [Full Text] [Related]

  • 7. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.
    Muzaffer MA, Dayer JM, Feldman BM, Pruzanski W, Roux-Lombard P, Schneider R, Laxer RM, Silverman ED.
    J Rheumatol; 2002 May 01; 29(5):1071-8. PubMed ID: 12022325
    [Abstract] [Full Text] [Related]

  • 8. Soluble interleukin-6 receptor in plasma and in lymphocyte culture supernatants of healthy individuals and patients with systemic lupus erythematosus and rheumatoid arthritis.
    Polgár A, Brózik M, Tóth S, Holub M, Hegyi K, Kádár A, Hodinka L, Falus A.
    Med Sci Monit; 2000 May 01; 6(1):13-8. PubMed ID: 11208277
    [Abstract] [Full Text] [Related]

  • 9. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
    Müller-Newen G, Küster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC.
    J Immunol; 1998 Dec 01; 161(11):6347-55. PubMed ID: 9834125
    [Abstract] [Full Text] [Related]

  • 10. Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes.
    De Benedetti F, Pignatti P, Bernasconi S, Gerloni V, Matsushima K, Caporali R, Montecucco CM, Sozzani S, Fantini F, Martini A.
    J Rheumatol; 1999 Feb 01; 26(2):425-31. PubMed ID: 9972980
    [Abstract] [Full Text] [Related]

  • 11. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
    Tesar V, Jirsa M, Zima T, Kalousová M, Bartunková J, Stejskalová A, Dostál C, Zabka J.
    Med Sci Monit; 2002 Jan 01; 8(1):BR24-9. PubMed ID: 11782670
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.
    Pignatti P, Ciapponi L, Galle P, Hansen MB, Massa M, Meazza C, Paonessa G, Novick D, Ciliberto G, Martini A, De Benedetti F.
    Clin Exp Immunol; 2003 Feb 01; 131(2):355-63. PubMed ID: 12562400
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
    Gaillard JP, Mani JC, Liautard J, Klein B, Brochier J.
    Eur Cytokine Netw; 1999 Mar 01; 10(1):43-8. PubMed ID: 10210772
    [Abstract] [Full Text] [Related]

  • 15. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis.
    Lotito AP, Campa A, Silva CA, Kiss MH, Mello SB.
    J Rheumatol; 2007 Apr 01; 34(4):823-30. PubMed ID: 17343316
    [Abstract] [Full Text] [Related]

  • 16. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases.
    Michalopoulou M, Nikolaou C, Tavernarakis A, Alexandri NM, Rentzos M, Chatzipanagiotou S, Cambouri C, Vassilopoulos D.
    Immunol Lett; 2004 Jul 15; 94(3):183-9. PubMed ID: 15275965
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J, Ohnesorge N, Rose-John S.
    Scand J Immunol; 2006 May 15; 63(5):321-9. PubMed ID: 16640655
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.
    Gaillard J, Pugnière M, Tresca J, Mani J, Klein B, Brochier J.
    Eur Cytokine Netw; 1999 Sep 15; 10(3):337-44. PubMed ID: 10477390
    [Abstract] [Full Text] [Related]

  • 19. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.
    Pulsatelli L, Boiardi L, Pignotti E, Dolzani P, Silvestri T, Macchioni P, Cantini F, Salvarani C, Facchini A, Meliconi R.
    Arthritis Rheum; 2008 Aug 15; 59(8):1147-54. PubMed ID: 18668607
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
    Nagaoka T, Sato S, Hasegawa M, Ihn H, Takehara K.
    J Rheumatol; 2000 Aug 15; 27(8):1917-21. PubMed ID: 10955333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.